FrancophonIA/ELRC3.0 huggingface dataset:
English: Stalevo is indicated for the treatment of adult patients with Parkinson's disease and end-of-dose motor fluctuations not stabilised on levodopa/dopa decarboxylase (DDC) inhibitor treatment.
Latvian: Stalevo lieto pieaugušiem pacientiem ar Parkinsona slimību un motorisku fluktuāciju devas iedarbības beigās, ja stabilizāciju nevar sasniegt ar levodopas/dopa dekarboksilāzes (DDC - dopa decarboxylase) inhibitoru terapiju.
English: How to transfer patients not currently treated with entacapone to Stalevo
Latvian: Kā pāriet uz terapiju ar Stalevo pacientiem, kuri patreiz nelieto entakaponu
English: For example, a patient taking one tablet of 50 mg/12.5 mg of levodopa/carbidopa with one tablet of entacapone 200 mg four times daily can take one 50 mg/12.5 mg/200 mg Stalevo tablet four times daily in place of their usual levodopa/carbidopa and entacapone doses.
Latvian: Piemēram, pacients, kurš lieto vienu tableti 50 mg/12,5 mg levodopu/karbidopu un vienu tableti entakaponu 200 mg četras reizes dienā, ierasto levodopas/karbidopas un entakapona devu vietā var lietot vienu Stalevo 50 mg/12,5 mg/200 mg tableti četras reizes dienā.
English: For some patients, Stalevo may not be well absorbed if it is taken with, or shortly after eating protein-rich food (such as meats, fish, dairy products, seeds and nuts).
Latvian: Dažiem pacientiem, lietojot Stalevo kopā ar olbaltumvielām bagātu ēdienu (gaļa, zivs, piena produkti, sēklas un rieksti) vai īsi pēc tam, Stalevo absorbcija var pasliktināties.
English: You may experience the following side effects: - Inability to resist the impulse to perform an action that could be harmful, which may include: - strong impulse to gamble excessively despite serious personal or family consequences - altered or increased sexual interest and behaviour of significant concern to you or to others for example, an increased sexual drive - uncontrollable excessive shopping or spending - binge eating (eating large amounts of food in a short time period) or compulsive eating
Latvian: Jums var attīstīties šādas blakusparādības: - Nespēja pretoties impulsam veikt darbības, kas varētu nodarīt kaitējumu Jums vai kādam citam; tās var būt: - spēcīgs impulss pārmērīgi spēlēt azartspēles neraugoties uz nopietnām sekām personīgajā vai ģimenes dzīvē; - izmainīta vai pastiprināta seksuāla interese un uzvedība, kas Jums vai citiem rada vērā ņemamas bažas, piemēram, pastiprināta dzimumtieksme;
English: According to this daily carbidopa dose, the maximum recommended daily dose of Stalevo 175 mg/43.75 mg/200 mg is 8 tablets per day and Stalevo 200 mg/50 mg/200 mg dose is 7 tablets per day.
Latvian: Saskaņā ar šo karbidopas dienas devu maksimālā ieteicamā Stalevo 175 mg/43,75 mg/200 mg diennakts deva ir 8 tabletes dienā un Stalevo 200 mg/50 mg/200 mg diennakts deva ir 7 tabletes dienā.
English: Stalevo contains sucrose
Latvian: Stalevo satur saharozi
English: Patients and carers should be made aware that behavioural symptoms of impulse control disorders including pathological gambling, increased libido, hypersexuality, compulsive spending or buying, binge eating and compulsive eating can occur in patients treated with dopamine agonists and/or other dopaminergic treatments containing levodopa including Stalevo.
Latvian: Pacienti un aprūpētāji jābrīdina, ka pacientiem, kuri tiek ārstēti ar dopamīna agonistiem un/vai citiem levodopu saturošiem dopamīnerģiskiem līdzekļiem, tādiem kā Stalevo, var attīstīties impulsu kontroles traucējumu uzvedības simptomi, tajā skaitā patoloģiska tieksme uz azartspēlēm, pastiprināta dzimumtieksme, hiperseksualitāte, kompulsīva naudas tērēšana vai iepirkšanās, pārēšanās un kompulsīva ēšana.
English: With inhibition of the decarboxylase by a DDC inhibitor, catechol-O-methyltransferase (COMT) becomes the major peripheral metabolic pathway catalyzing the conversion of levodopa to 3-Omethyldopa (3-OMD), a potentially harmful metabolite of levodopa.
Latvian: Tā katalizē levodopas konversiju par 3-O-metildopa (3OMD), potenciāli kaitīgu levodopas metabolītu.
English: No particular studies on the pharmacokinetics of carbidopa and levodopa in patients with hepatic impairment are reported, however, it is advised that Stalevo should be administered cautiously to patients with mild or moderate hepatic impairment.
Latvian: Nav ziņots par īpašiem karbidopas un levodopas farmakokinētikas pētījumiem, kas būtu veikti pacientiem ar aknu darbības traucējumiem, tomēr pacientiem ar viegliem un mēreniem aknu darbības traucējumiem Stalevo jāordinē piesardzīgi.
English: - If you are taking Stalevo 50 mg/12.5 mg/200 mg, 75 mg/18.75 mg/200 mg,
Latvian: - Ja Jūs lietojat Stalevo 50 mg/12,5 mg/200 mg, 75 mg/18,75 mg/200 mg, 100 mg/25 mg/200 mg,
English: - stomach ulcers or convulsions - if you experience prolonged diarrhoea consult your doctor as it may be a sign of inflammation of the colon - any form of severe mental disorder like psychosis - chronic wide-angle glaucoma, because your dose may need to be adjusted and the pressure in your eyes may need to be monitored.
Latvian: - jebkuras formas smagi psihiski traucējumi kā, piemēram, psihoze; - hroniska atvērta kakta glaukoma, jo varētu būt nepieciešama devas korekcija, kā arī acu spiediena mērījumi.
English: Stalevo contains three active substances (levodopa, carbidopa and entacapone) in one film-coated tablet.
Latvian: Stalevo viena apvalkotā tablete satur trīs aktīvās vielas (levodopu, karbidopu un entakaponu).
English: Stalevo 50 mg/12.5 mg/200 mg film-coated tablets Stalevo 75 mg/18.75 mg/200 mg film-coated tablets Stalevo 100 mg/25 mg/200 mg film-coated tablets Stalevo 125 mg/31.25 mg/200 mg film-coated tablets Stalevo 150 mg/37.5 mg/200 mg film-coated tablets Stalevo 175 mg/43.75 mg/200 mg film-coated tablets Stalevo 200 mg/50 mg/200 mg film-coated tablets
Latvian: Stalevo 50 mg/12,5 mg/200 mg apvalkotās tabletes Stalevo 75 mg/18,75 mg/200 mg apvalkotās tabletes Stalevo 100 mg/25 mg/200 mg apvalkotās tabletes Stalevo 125 mg/31,25 mg/200 mg apvalkotās tabletes Stalevo 150 mg/37,5 mg/200 mg apvalkotās tabletes Stalevo 175 mg/43,75 mg/200 mg apvalkotās tabletes Stalevo 200 mg/50 mg/200 mg apvalkotās tabletes
English: b. When initiating Stalevo therapy for patients currently treated with entacapone and levodopa/carbidopa in doses not equal to Stalevo tablets (50 mg/12.5 mg/200 mg or 75 mg/18.75 mg/200 mg or 100 mg/25 mg/200 mg or 125 mg/31.25 mg/200 mg or 150 mg/37.5 mg/200 mg or 175 mg/43.75 mg/200 mg or 200 mg/50 mg/200 mg), Stalevo dosing should be carefully titrated for optimal clinical response.
Latvian: Uzsākot terapiju ar Stalevo pacientiem, kuri patreiz lieto entakaponu un levodopu/karbidopu devās, kas nav ekvivalentas Stalevo tabletēm (50 mg/12,5 mg/200 mg vai 75 mg/18,75 mg/200 mg, vai 100 mg/25 mg/200 mg, vai 125 mg/31,25 mg/200 mg, vai 150 mg/37,5 mg/200 mg, vai 175 mg/43,75 mg/200 mg, vai 200 mg/50 mg/200 mg), Stalevo deva uzmanīgi jātitrē, kamēr tiek sasniegta optimāla klīniskā atbildes reakcija.
English: Studies in animals have shown reproductive toxicity of the separate compounds (see section 5.3).
Latvian: Pētījumos ar dzīvniekiem atsevišķiem savienojumiem konstatēja toksisku iedarbību uz reproduktivitāti
English: stalevo 75/18.75/200 mg [carton only]
Latvian: stalevo 75/18.75/200 mg [tikai uz kartona kastītes]
English: Few adverse reactions are known to be directly attributable to the active substance entacapone including diarrhoea and reddishbrown discolouration of urine.
Latvian: Zināms, ka dažas blakusparādības, ieskaitot caureju un urīna iekrāsošanos sarkanīgi-brūnā krāsā, ir tieši saistītas ar aktīvo vielu entakaponu.
English: stalevo 125/31.25/200 mg [carton only]
Latvian: stalevo 125/31.25/200 mg [tikai uz kartona kastītes]
English: stalevo 175/43.75/200 mg [carton only]
Latvian: stalevo 175/43.75/200 mg [tikai uz kartona kastītes]
English: How to transfer patients taking levodopa/DDC inhibitor (carbidopa or benserazide) preparations and entacapone tablets to Stalevo a. Patients who are currently treated with entacapone and with standard release levodopa/carbidopa in doses equal to Stalevo tablet strengths can be directly transferred to corresponding Stalevo tablets.
Latvian: Pacientiem, kuri patreiz terapijā saņem entakaponu un standarta iedarbības levodopu/karbidopu devās, kas ekvivalentas Stalevo tablešu stiprumiem, iepriekš minētās zāles var tieši aizvietot ar atbilstoša stipruma Stalevo tabletēm.
English: Stalevo contains sucrose (2.3 mg/tablet).
Latvian: Stalevo satur saharozi (2,3 mg tabletē).
English: 100 mg/25 mg/200 mg, 125 mg/31.25 mg/200 mg or 150 mg/37.5 mg/200 mg tablets, do not take more than 10 tablets per day.
Latvian: 125 mg/31,25 mg/200 mg vai 150 mg/37,5 mg/200 mg tabletes, nelietojiet vairāk par
English: stalevo 50/12.5/200 mg [carton only]
Latvian: stalevo 50/12.5/200 mg [tikai uz kartona kastītes]
English: Stalevo contains sucrose (1.89 mg/tablet).
Latvian: Stalevo satur saharozi (1,89 mg tabletē).
English: However, a direct switch from levodopa/DDC inhibitor to Stalevo is not recommended for patients who have dyskinesias or whose daily levodopa dose is above 800 mg.
Latvian: Tomēr pacientiem, kuriem ir diskinēzija vai diennakts levodopas deva pārsniedz 800 mg, tieša pāreja no levodopas/DDC inhibitora uz Stalevo nav ieteicama.
English: stalevo 150/37.5/200 mg [carton only]
Latvian: stalevo 150/37.5/200 mg [tikai uz kartona kastītes]
English: While the experience with total daily dose greater than 200 mg carbidopa is limited, the maximum recommended daily dose of entacapone is 2,000 mg and therefore the maximum dose is 10 tablets per day for the Stalevo strengths of 50 mg/12.5 mg/200 mg, 75 mg/18.75 mg/200 mg 100 mg/25 mg/200 mg, 125 mg/31.25 mg/200 mg and 150 mg/37.5 mg/200 mg.
Latvian: Tā kā kopējās karbidopas diennakts devas, lielākas par 200 mg, lietošanas pieredze ir ierobežota un entakapona maksimālā ieteicamā diennakts deva ir 2000 mg, maksimālā deva ir 10 tabletes dienā Stalevo stiprumiem 50 mg/12,5 mg/200 mg, 75 mg/18,75 mg/200 mg, 100 mg/25 mg/200 mg, 125 mg/31,25 mg/200 mg un 150 mg/37,5 mg/200 mg. Desmit Stalevo 150 mg/37,5 mg/200 mg stipruma tabletes atbilst 375 mg karbidopas dienas devai.
English: - Periodic evaluation of hepatic, haematopoietic, cardiovascular and renal function is recommended during extended therapy with Stalevo.
Latvian: - Ilgstošas terapijas laikā ar Stalevo nepieciešama periodiska aknu, hemopoētiskās sistēmas, sirds un asinsvadu sistēmas un nieru funkcijas izvērtēšana.
English: Some patients experience severe abnormal involuntary movements (dyskinesias), mood swings or other side effects after taking large doses of Stalevo.
Latvian: Dažiem pacientiem pēc lielu Stalevo devu lietošanas attīstās smagas, patoloģiskas, gribai nepakļautas kustības (diskinēzijas), garastāvokļa svārstības vai citas blakusparādības.
English: You may experience the following side effects: - Inability to resist the impulse to perform an action that could be harmful, which may include: - strong impulse to gamble excessively despite serious personal or family consequences - altered or increased sexual interest and behaviour of significant concern to you or to others, for example, an increased sexual drive - uncontrollable excessive shopping or spending - binge eating (eating large amounts of food in a short time period) or compulsive eating
Latvian: - izmainīta vai pastiprināta seksuāla interese un uzvedība, kas Jums vai citiem rada vērā ņemamas bažas, piemēram, pastiprināta dzimumtieksme; - nekontrolējama un pārmērīga iepirkšanās vai naudas tērēšana; - pārēšanās (liela ēdiena daudzuma apēšana īsā laika posmā) vai kompulsīva ēšana (neierasti liela ēdiena daudzuma ēšana, vairāk kā nepieciešams, lai apmierinātu savu izsalkumu).
English: stalevo 100/25/200 mg [carton only]
Latvian: stalevo 100/25/200 mg [tikai uz kartona kastītes]
English: LABELLING AND PACKAGE LEAFLET
Latvian: Stalevo ārējais izskats un iepakojums
English: Hepatic impairment: It is advised that Stalevo should be administered cautiously to patients with mild to moderate hepatic impairment.
Latvian: Aknu darbības traucējumi: pacientiem ar viegliem un mēreniem aknu darbības traucējumiem iesaka Stalevo nozīmēt piesardzīgi.
English: Stalevo 75 mg/18.75 mg/200 mg tablet comes in five different pack sizes (10, 30, 100, 130 or 175 tablets).
Latvian: Stalevo 75 mg/18,75 mg/200 mg tabletes pieejamas piecu lielumu iepakojumos (10, 30, 100, 130 vai 175 tabletes).
English: - Each Stalevo 125 mg/31.25 mg/200 mg tablet contains 125 mg of levodopa, 31.25 mg of carbidopa and 200 mg of entacapone.
Latvian: - Viena Stalevo 125 mg/31,25 mg/200 mg tablete satur 125 mg levodopas, 31,25 mg karbidopas un 200 mg entakapona.
English: stalevo 200/50/200 mg [carton only]
Latvian: stalevo 200/50/200 mg [tikai uz kartona kastītes]
English: - Each Stalevo 175 mg/43.75 mg/200 mg tablet contains 175 mg of levodopa, 43.75 mg of carbidopa and 200 mg of entacapone.
Latvian: - Viena Stalevo 175 mg/43,75 mg/200 mg tablete satur 175 mg levodopas, 43,75 mg karbidopas un 200 mg entakapona.
English: - Each Stalevo 75 mg/18.75 mg/200 mg tablet contains 75 mg of levodopa, 18.75 mg of carbidopa and 200 mg of entacapone.
Latvian: - Viena Stalevo 75 mg/18,75 mg/200 mg tablete satur 75 mg levodopas, 18,75 mg karbidopas un 200 mg entakapona.
English: Stalevo 125 mg/31.25 mg/200 mg tablet comes in five different pack sizes (10, 30, 100, 130 or 175 tablets).
Latvian: Stalevo 125 mg/31,25 mg/200 mg tabletes pieejamas piecu lielumu iepakojumos (10, 30, 100, 130 vai 175 tabletes).
English: Stalevo 175 mg/43.75 mg/200 mg tablet comes in five different pack sizes (10, 30, 100, 130 or 175 tablets).
Latvian: Stalevo 175 mg/43,75 mg/200 mg tabletes pieejamas piecu lielumu iepakojumos (10, 30, 100, 130 vai 175 tabletes).
English: Stalevo 150 mg/37.5 mg/200 mg: brownish or greyish red, elongated-ellipse shaped, unscored filmcoated tablets marked with ‘LCE 150' on one side.
Latvian: Stalevo 150 mg/37,5 mg/200 mg tabletes ir brūngani vai pelēcīgi sarkanas, garenas elipses formas, apvalkotās tabletes bez dalījuma līnijas, vienā pusē marķētas ar ‘LCE 150'.
English: - Each Stalevo 150 mg/37.5 mg/200 mg tablet contains 150 mg of levodopa, 37.5 mg of carbidopa and 200 mg of entacapone.
Latvian: - Viena Stalevo 150 mg/37,5 mg/200 mg tablete satur 150 mg levodopas, 37,5 mg karbidopas un 200 mg entakapona.
English: Stalevo 200 mg/50 mg/200 mg: dark brownish red, oval, unscored film-coated tablets marked with ‘LCE 200' on one side.
Latvian: Stalevo 200 mg/50 mg/200 mg tabletes: tumši sarkanbrūnas, ovālas, apvalkotās tabletes bez dalījuma līnijas, vienā pusē marķētas ar ‘LCE 200'.
English: Stalevo contains sucrose (1.9 mg/tablet).
Latvian: Stalevo satur saharozi (1,9 mg tabletē).
English: - Each Stalevo 100 mg/25 mg/200 mg tablet contains 100 mg of levodopa, 25 mg of carbidopa and 200 mg of entacapone.
Latvian: - Viena Stalevo 100 mg/25 mg/200 mg tablete satur 100 mg levodopas, 25 mg karbidopas un 200 mg entakapona.
English: Stalevo 200 mg/50 mg/200 mg tablet comes in five different pack sizes (10, 30, 100, 130 or 175).
Latvian: Stalevo 200 mg/50 mg/200 mg tabletes pieejamas piecu lielumu iepakojumos (10, 30, 100, 130 vai 175 tabletes).
English: Stalevo 125 mg/31.25 mg/200 mg: light brownish red, oval film-coated tablets marked with ‘LCE 125' on one side.
Latvian: Stalevo 125 mg/31,25 mg/200 mg tabletes ir gaiši brūngani sarkanas, ovālas, apvalkotās tabletes, vienā pusē marķētas ar ‘LCE 125'.
English: Stalevo 75 mg/18.75 mg/200 mg: light brownish red, oval film-coated tablets marked with ‘LCE 75' on one side.
Latvian: Stalevo 75 mg/18,75 mg/200 mg ir gaiši brūngani sarkanas, ovālas, apvalkotās tabletes, vienā pusē marķētas ar ‘LCE 75'.
English: - Each Stalevo 50 mg/12.5 mg/200 mg tablet contains 50 mg of levodopa, 12.5 mg of carbidopa and 200 mg of entacapone.
Latvian: - Viena Stalevo 50 mg/12,5 mg/200 mg tablete satur 50 mg levodopas, 12,5 mg karbidopas un 200 mg entakapona.
English: Stalevo contains sucrose (1.2 mg/tablet).
Latvian: Stalevo satur saharozi (1,2 mg tabletē).
English: Stalevo 175 mg/43.75 mg/200 mg: light brownish red, oval, unscored film-coated tablets marked with ‘LCE 175' on one side.
Latvian: Stalevo 175 mg/43,75 mg/200 mg tabletes ir gaiši brūngani sarkanas, ovālas, apvalkotās tabletes bez dalījuma līnijas, vienā pusē marķētas ar ‘LCE 175'.
English: Stalevo contains sucrose (1.6 mg/tablet).
Latvian: Stalevo satur saharozi (1,6 mg tabletē).
English: Stalevo 100 mg/25 mg/200 mg: brownish or greyish red, oval, unscored film-coated tablets marked with ‘LCE 100' on one side.
Latvian: Stalevo 100 mg/25 mg/200 mg tabletes ir brūngani vai pelēcīgi sarkanas, ovālas, apvalkotās tabletes bez dalījuma līnijas, vienā pusē marķētas ar ‘LCE 100'.
English: Impulse control disorders: Pathological gambling, increased libido, hypersexuality, compulsive spending or buying, binge eating and compulsive eating can occur in patients treated with dopamine agonists and/or other dopaminergic treatments containing levodopa including Stalevo (see section
Latvian: Pacientiem, kuri tiek ārstēti ar dopamīna agonistiem un/vai citiem levodopu saturošiem dopamīnerģiskiem līdzekļiem, tādiem kā Stalevo, var attīstīties patoloģiska tieksme uz azartspēlēm, pastiprināta dzimumtieksme, hiperseksualitāte, kompulsīva naudas tērēšana vai iepirkšanās, pārēšanās un kompulsīva ēšana (skatīt 4.4. apakšpunktu).
English: Stalevo 50 mg/12.5 mg/200 mg: brownish or greyish red, round, convex unscored film-coated tablets marked with ‘LCE 50' on one side.
Latvian: Stalevo 50 mg/12,5 mg/200 mg ir brūngani vai pelēcīgi sarkanas, apaļas, izliektas, apvalkotās tabletes bez dalījuma līnijas, vienā pusē marķētas ar ‘LCE 50'.
English: - Each Stalevo 200 mg/50 mg/200 mg tablet contains 200 mg of levodopa, 50 mg of carbidopa and 200 mg of entacapone.
Latvian: - Viena Stalevo 200 mg/50 mg/200 mg tablete satur 200 mg levodopas, 50 mg karbidopas un 200 mg entakapona.
English: Stalevo contains sucrose (1.4 mg/tablet).
Latvian: Stalevo satur saharozi (1,4 mg tabletē).
English: Stalevo 75 mg/18.75 mg/200 mg film-coated tablets levodopa/carbidopa/entacapone
Latvian: Stalevo 75 mg/18,75 mg/200 mg apvalkotās tabletes Levodopa/carbidopa/entacapone
English: No adverse reactions on fertility were observed in preclinical studies with entacapone, carbidopa or levodopa alone.
Latvian: Preklīniskajos pētījumos ar entakaponu, karbidopu vai levodopu vienu pašu netika novērotas nevēlamas blakusparādības saistībā ar fertilitāti.
English: The doses of other antiparkinsonian medicinal products may need to be adjusted when Stalevo treatment is substituted for a patient currently not treated with entacapone.
Latvian: Gadījumos, kad Stalevo terapija tiek ordinēta pacientam, kurš patreiz nesaņem entakaponu, var būt nepieciešama citu pretparkinsonisma līdzekļu devas korekcija.
English: Film-coating of 75/18.75/200 mg, 125/31.25/200 mg, 175/43.75/200 mg and 200/50/200 mg: Glycerol (85 per cent) (E422)
Latvian: Apvalks 75 mg/18,75 mg/200 mg, 125 mg/31,25 mg/200 mg, 175 mg/43,75 mg/200 mg un 200 mg/50 mg/200 mg:
English: EU/1/03/260/024 10 film-coated tablets EU/1/03/260/025 30 film-coated tablets EU/1/03/260/026 100 film-coated tablets EU/1/03/260/027 130 film-coated tablets EU/1/03/260/028 175 film-coated tablets
Latvian: EU/1/03/260/024 10 apvalkotās tabletes EU/1/03/260/025 30 apvalkotās tabletes EU/1/03/260/026 100 apvalkotās tabletes EU/1/03/260/027 130 apvalkotās tabletes EU/1/03/260/028 175 apvalkotās tabletes
English: (eating more food than normal and more than is needed to satisfy your hunger).
Latvian: - nekontrolējama un pārmērīga iepirkšanās vai naudas tērēšana; - pārēšanās (liela ēdiena daudzuma apēšana īsā laika posmā) vai kompulsīva ēšana (neierasti liela ēdiena daudzuma ēšana, vairāk kā nepieciešams, lai apmierinātu savu izsalkumu).
English: What Stalevo contains
Latvian: Ko Stalevo satur
English: EU/1/03/260/029 10 film-coated tablets EU/1/03/260/030 30 film-coated tablets EU/1/03/260/031 100 film-coated tablets EU/1/03/260/032 130 film-coated tablets EU/1/03/260/033 175 film-coated tablets
Latvian: EU/1/03/260/029 10 apvalkotās tabletes EU/1/03/260/030 30 apvalkotās tabletes EU/1/03/260/031 100 apvalkotās tabletes EU/1/03/260/032 130 apvalkotās tabletes EU/1/03/260/033 175 apvalkotās tabletes
English: EU/1/03/260/034 10 film-coated tablets EU/1/03/260/035 30 film-coated tablets EU/1/03/260/036 100 film-coated tablets EU/1/03/260/037 130 film-coated tablets EU/1/03/260/038 175 film-coated tablets
Latvian: EU/1/03/260/034 10 apvalkotās tabletes EU/1/03/260/035 30 apvalkotās tabletes EU/1/03/260/036 100 apvalkotās tabletes EU/1/03/260/037 130 apvalkotās tabletes EU/1/03/260/038 175 apvalkotās tabletes
English: Stalevo 175 mg/43.75 mg/200 mg film-coated tablets Levodopa/carbidopa/entacapone
Latvian: Stalevo 175 mg/43,75 mg/200 mg apvalkotās tabletes Levodopa/carbidopa/entacapone
English: EU/1/03/260/009 10 film-coated tablets EU/1/03/260/010 30 film-coated tablets EU/1/03/260/011 100 film-coated tablets EU/1/03/260/012 250 film-coated tablets EU/1/03/260/015 175 film-coated tablets EU/1/03/260/018 130 film-coated tablets
Latvian: EU/1/03/260/009 10 apvalkotās tabletes EU/1/03/260/010 30 apvalkotās tabletes EU/1/03/260/011 100 apvalkotās tabletes EU/1/03/260/012 250 apvalkotās tabletes EU/1/03/260/015 175 apvalkotās tabletes EU/1/03/260/018 130 apvalkotās tabletes
English: EU/1/03/260/005 10 film-coated tablets EU/1/03/260/006 30 film-coated tablets EU/1/03/260/007 100 film-coated tablets EU/1/03/260/008 250 film-coated tablets EU/1/03/260/014 175 film-coated tablets EU/1/03/260/017 130 film-coated tablets
Latvian: EU/1/03/260/005 10 apvalkotās tabletes EU/1/03/260/006 30 apvalkotās tabletes EU/1/03/260/007 100 apvalkotās tabletes EU/1/03/260/008 250 apvalkotās tabletes EU/1/03/260/014 175 apvalkotās tabletes EU/1/03/260/017 130 apvalkotās tabletes
English: Interactions between entacapone and imipramine and between entacapone and moclobemide have been investigated in single dose studies in healthy volunteers.
Latvian: Atsevišķas devas pētījumos veseliem brīvprātīgajiem pētīja mijiedarbību starp entakaponu un imipramīnu un starp entakaponu un moklobemīdu.
English: Stalevo 150 mg/37.5 mg/200 mg film-coated tablets levodopa/carbidopa/entacapone
Latvian: Stalevo 150 mg/37,5 mg/200 mg apvalkotās tabletes levodopa/carbidopa/entacapone
English: Stalevo 150 mg/37.5 mg/200 mg film-coated tablets Levodopa/carbidopa/entacapone
Latvian: Stalevo 150 mg/37,5 mg/200 mg apvalkotās tabletes Levodopa/carbidopa/entacapone
English: Stalevo 50 mg/12.5 mg/200 mg film-coated tablets levodopa/carbidopa/entacapone
Latvian: Stalevo 50 mg/12,5 mg/200 mg apvalkotās tabletes levodopa/carbidopa/entacapone
English: Stalevo 125 mg/31.25 mg/200 mg film-coated tablets levodopa/carbidopa/entacapone
Latvian: Stalevo 125 mg/31,25 mg/200 mg apvalkotās tabletes levodopa/carbidopa/entacapone
English: EU/1/03/260/001 10 film-coated tablets EU/1/03/260/002 30 film-coated tablets EU/1/03/260/003 100 film-coated tablets EU/1/03/260/004 250 film-coated tablets EU/1/03/260/013 175 film-coated tablets EU/1/03/260/016 130 film-coated tablets
Latvian: EU/1/03/260/001 10 apvalkotās tabletes EU/1/03/260/002 30 apvalkotās tabletes EU/1/03/260/003 100 apvalkotās tabletes EU/1/03/260/004 250 apvalkotās tabletes EU/1/03/260/013 175 apvalkotās tabletes EU/1/03/260/016 130 apvalkotās tabletes
English: EU/1/03/260/019 10 film-coated tablets EU/1/03/260/020 30 film-coated tablets EU/1/03/260/021 100 film-coated tablets EU/1/03/260/022 130 film-coated tablets EU/1/03/260/023 175 film-coated tablets
Latvian: EU/1/03/260/019 10 apvalkotās tabletes EU/1/03/260/020 30 apvalkotās tabletes EU/1/03/260/021 100 apvalkotās tabletes EU/1/03/260/022 130 apvalkotās tabletes EU/1/03/260/023 175 apvalkotās tabletes
English: Stalevo 100 mg/25 mg/200 mg film-coated tablets levodopa/carbidopa/entacapone
Latvian: Stalevo 100 mg/25 mg/200 mg apvalkotās tabletes levodopa/carbidopa/entacapone
English: Stalevo 200 mg/50 mg/200 mg film-coated tablets Levodopa/carbidopa/entacapone
Latvian: Stalevo 200 mg/50 mg/200 mg apvalkotās tabletes Levodopa/carbidopa/entacapone